KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Acquisitions: 2009-2016

  • Biomarin Pharmaceutical's Acquisitions was N/A to $1.3 million in Q4 2016 from the same period last year, while for Dec 2016 it was $568.4 million, marking a year-over-year change of. This contributed to the annual value of $2.8 million for FY2016, which is 99.48% down from last year.
  • Biomarin Pharmaceutical's Acquisitions amounted to $1.3 million in Q4 2016, which was down 99.75% from $538.4 million recorded in Q1 2015.
  • Over the past 5 years, Biomarin Pharmaceutical's Acquisitions peaked at $538.4 million during Q1 2015, and registered a low of $1.3 million during Q4 2016.
  • In the last 2 years, Biomarin Pharmaceutical's Acquisitions had a median value of $269.9 million in 2015 and averaged $269.9 million.